Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 37INDUSTRY 4NIH 2NETWORK 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 2CNS 2

Conditions

Prostatic Neoplasms 2Disease 2Brain Neoplasms 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × fluciclovine F-18 × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

NCT04410133 2025-08-28

REVELATE

Blue Earth Diagnostics

Phase 3 Completed
151 enrolled 29 charts
CNS

Brain Neoplasms, Disease

NCT04410367 2025-07-20

PURSUE

Blue Earth Diagnostics

Phase 2 Completed
23 enrolled 10 charts
CNS

Brain Neoplasms, Disease

NCT01176513 2014-02-14

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

GE Healthcare

Phase 2 Terminated
25 enrolled 4 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡